AbbVie (ABBV) is considered undervalued despite recent headwinds and slowing dividend growth, as its strong pipeline, particularly Skyrizi and Rinvoq, is projected to drive significant future earnings growth, making its forward P/E attractive.
Source Post
These 3 Dividend Stocks are UNDERVALUED!
DividendologyApr 13, 2026
The creator highlights three undervalued dividend stocks for April: MasterCard (MA), The Williams Company (WMB), and AbbVie (ABBV). MasterCard is presented as undervalued due to its low P/E multiple and strong historical performance, with projected upside. The Williams Company is favored for its fee-based revenue, inflation benefits, and growth tied to AI power demand and LNG exports. AbbVie, despite recent headwinds and slowing dividend growth, is seen as attractive due to its strong pipeline and projected earnings growth from new drugs like Skyrizi and Rinvoq.
Linked Mentions
Tickers discussed in this post
The Williams Company (WMB) is a compelling investment due to its structurally irreplaceable Transco pipeline, 95% fee-based revenue, inflation benefits, and growth from AI power demand and LNG exports, with projected double-digit distributable cash flow per share growth.
MasterCard (MA) is undervalued with a 5-year low P/E multiple, strong historical ROIC, expanding free cash flow margins, and projected 30.5% upside based on analyst targets and strong EPS growth.